• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Retina & Vitreous of Texas, PLLC informs patients of data security breach


Patients and employees, past and present, have had personal and protected health information acquired without authorization.

A red alert image with an unlocked lock and data leak. (Image Credit: AdobeStock/ZETHA_WORK)

The data belongs to current and former Retina & Vitreous employees and patients. (Image Credit: AdobeStock/ZETHA_WORK)

Retina & Vitreous of Texas, PLLC, announced they have become aware of a “data security incident” that may have affected personal and protected health information.

According to a press release, the data belongs to current and former Retina & Vitreous employees and patients.

Retina & Vitreous became aware of unusual activity within its network on February 1, 2023 and discovered there had been unauthorized access. According to the release, the company took immediate steps to secure the network and investigate the source of the breach.

Two weeks later, on February 15, 2023, it was determined some personal and protected health information may have been acquired without authorization in connection with the incident.

A review of the incident to identify all potentially affected individuals was completed on March 21, 2023. The review revealed the following information for current and former patients may have been affected as a result of the incident:

  • Names
  • Addresses
  • Diagnoses and treatment information
  • Insurance carrier information
  • Insurance subscriber identification numbers

Individuals whose information may have been affected were notified by Retina & Vitreous on April 10, 2023, over 2 months after the suspicious activity had been identified. The company has also offered resources to assist those affected.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.